Company intelligence / Profile preview

Kartos Therapeutics

Redwood City, California, United Stateskartosthera.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Navtemadlin has advanced to Phase 2/3 clinical trials in recurrent endometrial cancer. The company’s pipeline focuses on novel small molecule inhibitors targeting key oncogenic pathways such as MDM2 and BTK. No pivotal trial results or approvals have been reported as of May 2025.

Therapeutic areas: OncologyHematology
Modalities: Small molecules (notably MDM2 inhibitors)
Industry: Biotech

Drug pipeline

1 asset

navtemadlin

Beyond the preview

Go deeper on Kartos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kartos Therapeutics.